Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: Results from ExTRACT-TIMI 25

European Heart Journal

Volumn 28, Issue 9, 2007, Pages 1066-1071

  White, Harvey D ^a   Braunwald, Eugene ^b   Murphy, Sabina A ^b   Jacob, Ashok J ^c   Gotcheva, Nina ^d   Polonetsky, Leonid ^e   Antman, Elliott M ^b  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ST JOHN'S HOSPITAL   (United Kingdom)

^d NATIONAL HEART HOSPITAL   (Bulgaria)

^e REPUBLICAN SCIENTIFIC AND PRACTICAL CENTRE CARDIOLOGY   (Belarus)

Author keywords

Age; Enoxaparin; ExTRACT TIMI 25; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CONTROLLED STUDY; CREATININE CLEARANCE; DEATH; DRUG DOSE REDUCTION; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZATION; RECURRENT DISEASE; RISK ASSESSMENT; RISK REDUCTION; ST SEGMENT ELEVATION; STEADY STATE; TREATMENT OUTCOME;

ADULT; AGE FACTORS; DEATH, SUDDEN, CARDIAC; DOUBLE-BLIND METHOD; ENOXAPARIN; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; TREATMENT OUTCOME;

EID: 34547510596     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm081     Document Type: Article

References (12)

1. Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman M. Acute coronary care in the elderly (part 2): ST-Segment Elevation Myocardial Infarction. A Statement for Healthcare Professionals from the Acute Cardiac Care Subcommittee, Council of Clinical Cardiology, American Heart Association Endorsed by the Society of Geriatric Cardiology. Circulation, in press.
2. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial substudy. Circulation 2000;102:2031-2037.
3. White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005;112:3391-3399.
4. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002;13:745-753.
5. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
6. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, Bogaerts K, Danays T, Lindahl B, Makijarvi M, Verheugt F, Van de Werf F. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135-142.
7. Antman EM, Morrow DA, McCabe CH, Jiang F, White HD, Fox KA, Sharma D, Chew P, Braunwald E. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 2005;149:217-226.
8. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006;354:1477-1488.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. Bruno R, Baille P, Retout S, Vivier N, Veyrat-Follet C, Sanderink GJ, Becker R, Antman EM. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Br J Clin Pharmacol 2003;56:407-414.
11. TIMI 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. J Am Coll Cardiol 1997;29:1474- 1482.
12. Granger CB, Alexander JH, Lesaffre E, Wallentin L, Armstrong PW, Van de Werf F. Differential impact of antithrombotic treatments combined with tenecteplase in the elderly with acute myocardial infarction: results from ASSENT-3. J Am Coll Cardiol 2002;39:306A.